中国实验诊断学
中國實驗診斷學
중국실험진단학
Chinese Journal of Laboratory Diagnosis
2015年
10期
1689-1692
,共4页
红斑狼疮%系统性%趋化因子 CXCL13%受体 CXCR5
紅斑狼瘡%繫統性%趨化因子 CXCL13%受體 CXCR5
홍반랑창%계통성%추화인자 CXCL13%수체 CXCR5
Lupus erythematosus%systemic%chemohine CXCL13%receptor CXCR5
目的:检测系统性红斑狼疮(SLE)患者血清趋化因子 CXCL13水平及其受体 CXCR5在外周血 B 细胞、滤泡辅助 T 细胞(TFH)上的表达,分析 CXCL13、TFH 细胞水平与疾病活动的相关性,探讨 CXCL13及 CXCR5受体在SLE 发病机制中的可能作用。方法酶联免疫吸附法(ELISA)检测58例 SLE 患者血浆 CXCL13水平,以流式细胞术检测24例 SLE 患者外周血中 CXCR5在 CD19+B 细胞、TFH 细胞上的表达水平。结果①血清 CXCL13SLE 患者组为365.96±216.02(pg/ml),高于健康对照组145.66±207.25(pg/ml)(P <0.01)与 SLE 缓解组167.19±145.37(pg/ml);CXCL13水平与 SLE 患者的 SLEDAI 评分、抗核抗体滴度呈正相关(P <0.05)。②SLE 患者 B 细胞 CXCR5的表达率为79.03±20.59%,显著低于健康对照组94.25±4.52%,P <0.05。③:SLE 活动组 TFH 细胞水平(%)15.36±7.01高于健康对照组8.92±5.11%,P <0.05;TFH 细胞水平与患者的 SLEDAI 评分呈正相关(P <0.05),与 C3、dsDNA 无相关性(均 P >0.05)。结论SLE 患者外周血 CXCL13及表达其受体 CXCR5的 TFH 细胞水平增高,并与病情的活动性相关,提示 CXCL13有可能积极参与至 SLE 的发病机制中,并更有可能为 SLE 的治疗提供新的靶点。
目的:檢測繫統性紅斑狼瘡(SLE)患者血清趨化因子 CXCL13水平及其受體 CXCR5在外週血 B 細胞、濾泡輔助 T 細胞(TFH)上的錶達,分析 CXCL13、TFH 細胞水平與疾病活動的相關性,探討 CXCL13及 CXCR5受體在SLE 髮病機製中的可能作用。方法酶聯免疫吸附法(ELISA)檢測58例 SLE 患者血漿 CXCL13水平,以流式細胞術檢測24例 SLE 患者外週血中 CXCR5在 CD19+B 細胞、TFH 細胞上的錶達水平。結果①血清 CXCL13SLE 患者組為365.96±216.02(pg/ml),高于健康對照組145.66±207.25(pg/ml)(P <0.01)與 SLE 緩解組167.19±145.37(pg/ml);CXCL13水平與 SLE 患者的 SLEDAI 評分、抗覈抗體滴度呈正相關(P <0.05)。②SLE 患者 B 細胞 CXCR5的錶達率為79.03±20.59%,顯著低于健康對照組94.25±4.52%,P <0.05。③:SLE 活動組 TFH 細胞水平(%)15.36±7.01高于健康對照組8.92±5.11%,P <0.05;TFH 細胞水平與患者的 SLEDAI 評分呈正相關(P <0.05),與 C3、dsDNA 無相關性(均 P >0.05)。結論SLE 患者外週血 CXCL13及錶達其受體 CXCR5的 TFH 細胞水平增高,併與病情的活動性相關,提示 CXCL13有可能積極參與至 SLE 的髮病機製中,併更有可能為 SLE 的治療提供新的靶點。
목적:검측계통성홍반랑창(SLE)환자혈청추화인자 CXCL13수평급기수체 CXCR5재외주혈 B 세포、려포보조 T 세포(TFH)상적표체,분석 CXCL13、TFH 세포수평여질병활동적상관성,탐토 CXCL13급 CXCR5수체재SLE 발병궤제중적가능작용。방법매련면역흡부법(ELISA)검측58례 SLE 환자혈장 CXCL13수평,이류식세포술검측24례 SLE 환자외주혈중 CXCR5재 CD19+B 세포、TFH 세포상적표체수평。결과①혈청 CXCL13SLE 환자조위365.96±216.02(pg/ml),고우건강대조조145.66±207.25(pg/ml)(P <0.01)여 SLE 완해조167.19±145.37(pg/ml);CXCL13수평여 SLE 환자적 SLEDAI 평분、항핵항체적도정정상관(P <0.05)。②SLE 환자 B 세포 CXCR5적표체솔위79.03±20.59%,현저저우건강대조조94.25±4.52%,P <0.05。③:SLE 활동조 TFH 세포수평(%)15.36±7.01고우건강대조조8.92±5.11%,P <0.05;TFH 세포수평여환자적 SLEDAI 평분정정상관(P <0.05),여 C3、dsDNA 무상관성(균 P >0.05)。결론SLE 환자외주혈 CXCL13급표체기수체 CXCR5적 TFH 세포수평증고,병여병정적활동성상관,제시 CXCL13유가능적겁삼여지 SLE 적발병궤제중,병경유가능위 SLE 적치료제공신적파점。
Objective To detect the s levels of chemokine CXCL13 and the expression of receptor CXCR5 on CD19+B cell and CD4+Th cells in patients with systemic lupus erythematosus (SLE),to access the relationship between CXCL13、TFH and SLE disease activity.Methods The serum levels of CXCL13 were measured by enzyme linked im-munosorbent assay (ELISA)in 58 patients with SLE and frequencies of CD19+CXCR5B cells and CD4CXCR5 T cell w ere analyzed b y flow-cytometry in 24 patients with SLE.Results ①Serum CXCL13 concentration was significantly higher in SLE active patients than inactive SLE group and NC group (P <0.05);Increase in CXCL13 concentration correlated positively and significantly with SLEDAI,Anti-nuclear antibody titers (all P <0.05).② the frequencies of CXCR5 on CD19+ B cell were significantly down regulated in SLE patients whiling comparing with NC group.③The percentage of CXCR5 in CD4+T cells was increased jn patients with SLE compared with healthy controls,P <0.05. There were positive co-relationship between TFH and SLEDAI.Conclusion Elevated CXCL13 level and increased fre-quency of circulating Tfh cells in SLE patients are associated with disease activity,indicating CXCL13 and its receptor CXCR5 may play an important role in the pathogenesis of SLE.